West Pharmaceutical Services: GLP-1 Dependency, Emerging Oral-Formulation Risks, and Insufficient Diversification Justify Hold Rating

Morgan Stanley analyst Kallum Titchmarsh has maintained their neutral stance on WST stock, giving a Hold rating yesterday.

Kallum Titchmarsh has given his Hold rating due to a combination of factors related to West Pharmaceutical Services’ growth drivers and risk profile. He notes that recent performance has been heavily supported by elastomer components used in injectable GLP-1 therapies, and that the emerging shift toward oral GLP-1 formulations introduces uncertainty around how sustainable this contribution will be. His analysis suggests that, even under relatively favorable assumptions about the future balance between injectable and oral GLP-1 administration, West would still need a notable acceleration in its non-GLP business to achieve its long-term organic growth target of 7–9%.
Kallum Titchmarsh also highlights that the company’s premium valuation depends on investor confidence in this long-term growth framework, yet current evidence of diversification beyond GLP-linked products is not compelling enough to fully justify a more positive stance. While near- to mid‑term financials may not show immediate deterioration, he views the rollout of oral GLP-1 drugs as a real strategic risk that could weigh on sentiment and the growth algorithm over time. Given these dynamics—solid current GLP-driven momentum offset by structural uncertainties and the need for broader portfolio strength—he concludes that a Hold (Equal-weight) rating is appropriate until clearer proof of sustainable, diversified growth emerges.

In another report released yesterday, TipRanks – OpenAI also downgraded the stock to a Hold with a $258.00 price target.